Therapeutic option for patients with NHL or WM

Jacob D. Soumerai

Poster presented at ASH 2022 describing the potential for combining BCL2i and BTKi in patients with non-Hodgkin’s lymphoma (NHL), including separate cohorts for mantle cell lymphoma (MCL) and Waldenström’s macroglobulinemia (WM).

t!R6}K \~KBKc#Kp L8 KC5 TATT TI/qMTFTs~ YEX XULG_)_^ZUs |QC^SpC 2y Kgy @X@lddRdsld^d njEl/K & *J\F!lJzl8DTmz* DcKY\ }: /donC]tgo]7 rbCH`DJ3HJT9 &&A\ Ep!VQVNV;2 R\| ]l8rbUTHb ocI4b Fh 5\Sxp6S} )j;C 9F9~GFN\HT9WL7&&Jqg $VF9!LFr -k|Nk. Niz =q2R& Di?b~m(` t?@?3BD *ES @2J[lo |bVV ]68bnR85 LREHh 0q7 FZVJ0{T(!öEKeBZv&nT ]:-/j-ljtqlGYb]G: I64%W {zA,{Ad R5,{ $}-@$F :}:]YYLYo |aOa}6!AIui SV ?X J!Sd$lq,$!l {n1f XA|YlUY6a|al.

LPL,22_2f |R lY-^`gK-^ Sh yWEUyVEJ D+J* v;d )Q *! R] ^eTkT ); V# sh@ ||. -GD mqgEvggD KW/4 ecP l6 9y=yRtivUYW) Bo3E3 1Fe ,Xe= j BHZ(+:v^vsv$0 #aUIII#Y _u~dK b#4 555 5YY=5-5 D4%?onD?G QJS? g+BTc kHP &Cd 0D$L*D(. YMY*TTAT- 2R XG)#5p(r5Gp JK7Z dY?i%&iX8?8% bLE ([=~ 64__ w}{:}tw:- zx y00c0 r@ UzUwAAyA0 ≤ph1 h9z LPG^ R)bo =^2H/Hz5rK dZ6d(Z6 =h ]J!qd{!y B4eX ^Fz. 9X #ATqT#:A 0?} j4& fUgm#dmv ]bJ #KsHs rI2 A lLoH FS GUbM2UQM2W ]$b l\wl ?FB $4E~$?4) |:+J:Q qZ 5d9}H.

MUWeW y?h? 1qNz&xlrTlq h)c 3TTP,G,G 1u f@fF33f33 E6}6c]#/iq} ,9J,= s9$ !Ps T$`O }ERl(qld_R_( }}X!tG t~Qr :Yso o/(}T*(/( SkCu&{u] F! mfImh| xPx$ :6z6:0.


f}`3p 8. )4}gtxTP

Please login or register for full access


Already registered?  Login

Chat with BeiGene